This was a multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating intra-articular LNA043 in patients with knee osteoarthritis.
The study was structured as a two-period design: * A 2-year Core Period, followed by * A 3-year Extension Period, consisting of 2 years of continued treatment and 1 year of follow-up, totaling 5 years. Participants were randomized in a 1:1:1:1:1 ratio into five treatment arms: * LNA043 20 mg Q4w ×3, repeated every 6 months. * LNA043 40 mg ×1 and placebo Q4w ×2, repeated every 6 months. * LNA043 40 mg Q4w ×3 followed six months later by placebo Q4w ×3, repeated every 12 months. * LNA043 40 mg Q4w ×3, repeated every 6 months. * Placebo Q4w ×3, repeated every 6 months. All injections were administered intra-articularly (i.a.) to the target knee. Placebo injections (saline solution) were used throughout the study to maintain blinding and ensure consistency in injection frequency across arms. During the Extension Period: * Participants from the 6-month cycle arms continued with a single injection of the same LNA043 dose every 6 months. * Participants from the 12-month cycle arm received LNA043 40 mg every 12 months and placebo every other 6 months. * Participants who received placebo during the Core Period continued with a single injection of the same placebo every 6 months. The final year of the Extension Period was a no-treatment follow-up phase for all participants. The study was terminated early following the Week 104 primary endpoint analysis due to lack of effect.There was no safety related reasons for early termination or safety concerns for the subjects in the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
576
LNA043 was administered intra-articularly in various dosing regimens across four active treatment arms: * Arm 1: LNA043 40 mg Q4W ×3, repeated every 6 months * Arm 2: LNA043 40 mg Q4W ×3, followed six months later by placebo Q4W ×3, repeated every 12 months * Arm 3: LNA043 20 mg Q4W ×3, repeated every 6 months * Arm 4: LNA043 40 mg ×1, repeated every 6 months During the Extension Period, participants continued with either single injections every 6 or 12 months, based on their Core Period assignment.
Placebo (saline solution for injection) was administered intra-articularly in various regimens to maintain blinding and ensure consistency in injection frequency across all arms: * Arm 2: Placebo Q4W ×3 administered six months after LNA043 Q4W ×3 * Arm 4: Two placebo injections following LNA043 40 mg ×1 to complete the 3-injection cycle every 6 months * Placebo Arm: Placebo Q4W ×3 every 6 months throughout the Core and Extension Periods. In the Extension Period, placebo injections were used to match the frequency of active arms.
Change From Baseline in Cartilage Thickness in the Central Medial Tibiofemoral Compartment (cMTFC) of the Target Knee at Week 104
The cartilage thickness in the cMTFC of the target knee was assessed by quantitative Magnetic Resonance Imaging (qMRI). The change from baseline at Week 104 was calculated. A negative change from baseline indicated a reduction in the cartilage thickness
Time frame: Baseline, Week 104
Change From Baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Scale at Week 104
The WOMAC is a widely used self-administered health status measure used in assessing pain, stiffness, and function in patients with OA of the hip or knee. The WOMAC pain scale included five questions about pain during specific activities such as walking on a flat surface, going up or down stairs, during the night while in bed, sitting or lying down and standing upright. Each item was rated on an 11-point numeric rating scale (NRS) from 0 (no pain) to 10 (worst imaginable pain). The WOMAC pain subscale was calculated as the sum of the 5 pain items, ranging from 0 to 50, with higher scores indicating worse pain. Scores were then re-scaled to normalized 0-100. Change from baseline at Week 104 was assessed, where a negative change indicated improvement.
Time frame: Baseline, Week 104
Change From Baseline in WOMAC Pain Walking on a Flat Surface Item at Week 104
The WOMAC is a widely used self-administered health status measure used in assessing pain, stiffness, and function in patients with OA of the hip or knee. The WOMAC pain scale included five questions about pain during specific activities such as walking on a flat surface, going up or down stairs, during the night while in bed, sitting or lying down and standing upright. Each item was rated on an 11-point NRS from 0 (no pain) to 10 (worst imaginable pain). Scores were then re-scaled to normalized 0-100. The change from baseline at Week 104 in WOMAC pain walking on a flat surface item score was assessed, where a negative change indicated improvement.
Time frame: Baseline, Week 104
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Elite Clinical Studies
Phoenix, Arizona, United States
Tucson Orthopedic Institute PC
Tucson, Arizona, United States
Sharps Hospital Grossmont
La Mesa, California, United States
Clinical Trials Research
Lincoln, California, United States
Long Beach Clinical Trials
Long Beach, California, United States
Artemis Institute Clinical Research
Riverside, California, United States
Northern California Research
Sacramento, California, United States
Arthemis Clinical Research
San Diego, California, United States
Stamford Therapeutics Consortium LLC
Stamford, Connecticut, United States
Sensible Healthcare
Ocoee, Florida, United States
...and 65 more locations
Change From Baseline in WOMAC Function Scale at Week 104
The WOMAC is a widely used self-administered health status measure used in assessing pain, stiffness, and function in patients with OA of the hip or knee. The WOMAC functional subscale included 17 questions that measured how OA affected their daily activities including going up and down stairs, sitting, standing, squatting to the floor, walking, getting in a car, shopping, putting on and taking off socks, getting out of bed, lying in bed, bathing, sitting, getting on and off the toilet, heavy domestic duties, and light domestic duties. Each item was rated on an 11-point NRS from 0 (no limitation) to 10 (extreme limitation). The WOMAC functional subscale was calculated as the sum of the 17 pain items, ranging from 0 to 170, with higher scores indicating more severe limitations. Scores were then re-scaled to normalized 0-100. Change from baseline at Week 104 was assessed, where a negative change indicated improvement.
Time frame: Baseline, Week 104
Change From Baseline in Cartilage Thickness in the Total Tibiofemoral Compartments (TFCs) in the Target Knee at Week 104
The cartilage thickness in the total TFC in the target knee was assessed by qMRI. The change from baseline at Week 104 was calculated. A negative change from baseline indicated a reduction in the cartilage thickness.
Time frame: Baseline, Week 104
Change From Baseline in Cartilage Thickness in the Medial TFCs in the Target Knee at Week 104
The cartilage thickness in the medial TFC in the target knee was assessed by qMRI at Week 104. The change from baseline at Week 104 was calculated. A negative change from baseline indicated a reduction in the cartilage thickness.
Time frame: Baseline, Week 104
Change From Baseline in Cartilage Thickness in the Lateral TFCs in the Target Knee at Week 104
The cartilage thickness in the lateral TFC in the target knee was assessed by qMRI at Week 104. The change from baseline at Week 104 was calculated. A negative change from baseline indicated a reduction in the cartilage thickness.
Time frame: Baseline, Week 104
Change From Baseline at Week 104 in the Osteoarthritis Research Society International (OARSI) Physical Performance-based Assessment: 40-meter (4×10m) Fast-paced Walk Test
The OARSI 40-meter (4x10m) fast-paced walk test assessed walking speed and functional mobility over a short distance. Participants were instructed to walk as quickly and safely as possible along a 10-meter walkway, turn around a cone, and repeat the sequence four times for a total of 40 meters. The time taken to complete the 40 meters was recorded. A shorter time indicated better performance. The change from baseline at Week 104 was assessed. A negative change from baseline indicated improvement in physical function.
Time frame: Baseline, Week 104
Change From Baseline at Week 104 in the OARSI Physical Performance-based Assessments: 30-second Chair Stand Test
The OARSI 30-second chair stand test assessed the number of times a participant stood up from a seated position and sat back down within 30 seconds. A higher number of repetitions reflected better lower limb strength and physical function. The change from baseline was evaluated at Week 104. A positive change from baseline indicated an improvement in physical function.
Time frame: Baseline, Week 104
Change From Baseline at Week 104 in the OARSI Physical Performance-based Assessments: 6-minute Walking Test
This performance-based endpoint assessed submaximal aerobic capacity and functional walking ability. Participants were instructed to walk as far as possible in six minutes along a standardized, level walkway, following the guidelines of the American Thoracic Society. The total distance walked in meters was recorded. A greater distance walked indicated better physical function. The change from baseline was evaluated at Week 104. A positive change from baseline reflected an improvement in physical function.
Time frame: Baseline, Week 104
Percentage of Participants With Loss of Medial Minimum Joint Space Width ≥0.70 mm From Baseline at Week 104
Percentage of participants who experienced loss of medial minimum joint space width ≥ 0.70 mm from baseline as measured by X-ray at Week 104
Time frame: Baseline, Week 104
Number of Participants With Anti-drug Antibodies (ADAs) and Neutralizing Antibodies (NAb) Status
ADA status was categorized based on baseline and post-baseline results as follows: Subjects with ADA-negative sample at baseline: Participants with a negative ADA result at baseline. Subjects with ADA-positive sample at baseline: Participants with a positive ADA result at baseline. Subjects with ADA-positive NAb sample at baseline: Participants with a positive ADA and neutralizing antibody (NAb) result at baseline. Subjects with treatment-emergent ADA-positive: Participants with a positive ADA result post-baseline and a negative result at baseline. Subjects with treatment-emergent ADA-negative: Participants with a negative ADA result at baseline and all post-baseline samples also negative. Subjects with treatment-emergent ADA-inconclusive: Participants who did not meet any of the above definitions
Time frame: From baseline up to end of study, assessed up to 3.6 years